[GTXI] GTx, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.44 Change: -0.06 (-1.09%)
Ext. hours: Change: 0 (0%)

chart GTXI

Refresh chart

Strongest Trends Summary For GTXI

GTXI is in the medium-term down -39% below S&P in 5 months and down -95% in 1 year. In the long-term down -99% in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: GTx, Inc., a biopharmaceutical company, is engaged in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. It is involved in developing Enobosarm 3 mg, an androgen receptor modulator, which is in Phase III clinical trial for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer; and Enobosarm 9 mg, which is in Phase II clinical trial for the treatment of AR positive and ER positive metastatic breast cancer in women. The company also develops Capesaris, an oral nonsteroidal estrogen receptor alpha agonist that is in Phase II clinical trial for secondary hormonal therapy in men with metastatic or nonmetastatic castration resistant prostate cancer. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-71.66% ROE-206.41% ROI
Current Ratio1.52 Quick Ratio Long Term Debt/Equity Debt Ratio1.88
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities980 K Cash From Operating Activities-4.7 M Gross Profit
Net Profit-2.38 M Operating Profit-5.06 M Total Assets45.78 M Total Current Assets45.34 M
Total Current Liabilities29.87 M Total Debt Total Liabilities29.89 M Total Revenue
Technical Data
High 52 week25.24 Low 52 week0.75 Last close0.96 Last change-0.76%
RSI67.37 Average true range0.11 Beta1.02 Volume15.52 K
Simple moving average 20 days4.46% Simple moving average 50 days-21.42% Simple moving average 200 days-91.73%
Performance Data
Performance Week-2.67% Performance Month-19.32% Performance Quart-40.37% Performance Half-93.74%
Performance Year-92.1% Performance Year-to-date23.09% Volatility daily6.8% Volatility weekly15.21%
Volatility monthly31.17% Volatility yearly107.96% Relative Volume135.53% Average Volume640.71 K
New High New Low

News

2019-03-22 14:14:00 | Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

2019-03-22 06:00:00 | Editorial: GTx's fall is not a failure

2019-03-20 21:00:00 | Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm

2019-03-13 08:10:57 | GTx's legacy: The once-promising pillar of Memphis' 'biotech core'

2019-03-13 08:10:57 | Behind the merger and relocation of GTx, the once-promising pillar of Memphis' 'biotech core'

2019-03-11 14:42:00 | GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of GTx, Inc. - GTXI

2019-03-07 18:05:00 | GTX, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

2019-03-07 10:33:12 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of GTx, Inc. to Oncternal Therapeutics, Inc. is Fair to Shareholders

2019-03-07 09:40:00 | Watch These Four Healthcare Stocks Set The Standard on Thursday

2019-03-07 08:10:22 | GTx merges with biotech firm, new HQ to be based in San Diego

2019-03-07 07:00:00 | GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies

2019-02-13 12:28:31 | CEOs of ServiceMaster, First Horizon, AutoZone react to FedEx Logistics move

2019-02-07 08:25:00 | Analysis: Positioning to Benefit within Skyworks Solutions, Atmos Energy, Ellie Mae, ScanSource, REV Group, and GTx — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-08 09:00:00 | Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences — Renewed Outlook, Key Drivers of Growth

2018-10-31 02:03:22 | [$$] Spinal implants enable paraplegic patients to walk again

2018-10-25 08:22:12 | Zacks.com featured highlights include: Guess?, GTX, NCI, EMCOR and Mitek

2018-10-24 07:49:11 | What Overvaluation? 5 Stocks With Rising P/E Are Good Buys

2018-10-22 07:03:17 | GTx: 3Q Earnings Snapshot

2018-10-22 07:00:00 | GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-10-16 12:14:08 | Who makes what: Big bucks paid to Memphis' top company execs

2018-10-16 08:50:00 | New Research Coverage Highlights Adesto Technologies, Pain Therapeutics, U.S. Global Investors, GTx, Columbus McKinnon, and Baytex Energy — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-08 08:00:00 | Today’s Research Reports on Stocks to Watch: GTx and TrovaGene

2018-09-24 08:00:00 | Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics

2018-09-21 16:38:00 | Why GTx, Tilray, and United Natural Foods Slumped Today

2018-09-21 15:33:00 | Here's Why GTx, Inc. Dropped Over 92% Today

2018-09-21 13:35:32 | Pot-Enthusiasts Beware: GTx Shows How a Hot Trend Can Reverse

2018-09-21 08:39:00 | GTx Inc. stock drops 94% premarket after phase 2 trial failure

2018-09-21 08:00:00 | GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence

2018-09-18 08:55:12 | Are Options Traders Betting on a Big Move in GTx GTXI Stock?

2018-08-30 07:00:00 | GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference

2018-08-20 08:20:00 | Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-14 07:07:33 | GTx: 2Q Earnings Snapshot

2018-08-14 07:00:00 | GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results

2018-08-13 09:45:00 | VKTX: Data from P2 Trial of VK2809 in 4Q18…

2018-06-25 07:00:00 | GTx Added to the Russell 3000® Index

2018-06-05 07:40:00 | Detailed Research: Economic Perspectives on First Mid-Illinois Bancshares, GTx, Ferroglobe, SunOpta, Bandwidth, and Carbonite — What Drives Growth in Today's Competitive Landscape

2018-05-31 07:00:00 | GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference

2018-05-18 14:00:00 | GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

2018-05-16 10:59:08 | Does GTx Inc’s NASDAQ:GTXI -71.74% Earnings Drop Reflect A Longer Term Trend?

2018-05-15 07:04:33 | GTx: 1Q Earnings Snapshot

2018-05-15 07:00:00 | GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results

2018-05-13 10:06:03 | The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

2018-04-16 07:00:00 | GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting

2018-04-13 08:15:00 | Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-04-11 07:10:00 | Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI

2018-04-09 07:00:00 | GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

2018-03-15 08:00:00 | Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group — Future Expectations, Projections Moving into 2018

2018-03-12 16:21:19 | GTx reports 4Q loss

2018-03-12 16:05:00 | GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

2018-03-05 16:40:00 | Why Square, CF Industries Holdings, and GTx Jumped Today